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Abstract 
Background: In current guidelines, endoscopic ultrasound with fine-needle aspiration (EUS-FNA) is recommended 
in pancreatic cystic lesions (PCLs) with worrisome features (size ≥ 3 cm, mural nodule, or Wirsung dilation).
Objective: To evaluate the diagnostic ability and assess the accuracy of EUS-FNA in PCLs smaller than 3 cm.
Methods: Retrospective study of PCLs < 3 cm (2007–2016) undergoing EUS-FNA. Clinical, EUS and pancreatic cystic 
fluid (PCF) data were prospectively registered. Performance of EUS-FNA with PCF analysis for the detection of malig-
nancy and accuracy in surgical cohort were analyzed.
Results: We evaluated 115 patients with PCLs < 3 cm who underwent EUS-FNA. 19 patients underwent surgery, 7 
had malignant, 8 pre-malignant, and the remaining 4 benign lesions. Mass/mural nodule was present in 27% of the 
cysts, CEA level was higher than 192 ng/mL in 39.4% of patients, and only 35% of cytologic samples were informative. 
Nevertheless, additional FNA for PCF analysis improved the diagnostic performance of EUS imaging—AUC = 0.80 
versus AUC = 60.
Conclusion: EUS-FNA has good accuracy in PCLs < 3 cm. It confirmed malignancy even in lesions without worrisome 
features (nodule/mass), with two in every five resections showing high-risk/malignant lesions. EUS-FNA was also use-
ful to diagnose benign cysts, possibly allowing surveillance to be stopped in one in every five patients.
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Background
Pancreatic cancer is the 4th leading cause of cancer death 
in the USA and it is expected to be the 2nd by 2030. 
Mucinous pancreatic cysts are believed to be premalig-
nant and would represent an excellent opportunity for 
early diagnosis in this malignancy [1].
The prevalence of pancreatic cysts over 1  cm in the 
general population is around 2% and cyst prevalence 
increases with age [2] making differential diagnosis of 
these lesions, a true challenge. Furthermore, the wide-
spread use of abdominal imaging led to a significant 
increase in the diagnosis of asymptomatic pancreatic 
cystic lesions (PCLs) [3], including benign/inflamma-
tory cysts. [e.g. serous cystadenomas (SCAs), pseudo-
cysts], pre-malignant [intraductal papillary mucinous 
neoplasms (IPMNs) and mucinous cystic neoplasms 
(MCNs)], and malignant cysts [cystic adenocarcinomas 
(ADCs), cystic neuroendocrine tumors (NETs), acinar 
cell carcinomas, etc.].
The key question for pancreatic cyst management is to 
distinguish patients harboring advanced neoplasia who 
should be submitted to surgery, from those with pre-
malignant lesions who require surveillance, and those 
Open Access
*Correspondence:  sandrarfaias@hotmail.com
1 Gastroenterology Department, Instituto Português de Oncologia 
de Lisboa Francisco Gentil EPE, Rua Prof Lima Basto, 1099-023 Lisbon, 
Portugal
Full list of author information is available at the end of the article
Page 2 of 8Faias et al. BMC Gastroenterol          (2020) 20:413 
with benign lesions who can be safely released from sur-
veillance programs.
Imaging per se lacks accuracy for differential diagnosis 
of PCLs because there are no clear pathognomonic fea-
tures of each cyst type, although some findings may sug-
gest a particular diagnosis.
There is probably no other health disorder so preva-
lent and potentially severe, for which evidence is so low, 
due to the paucity of randomized trials performed. An 
attempt to summarize the best available evidence for the 
clinical management of PCLs has been made by experts 
in the field with the preparation of several recent guide-
lines [4–7].
In the absence of robust prospective data, current 
guidelines for management of PCLs are mostly driven by 
low-quality evidence, consensus, and opinion of experts 
[4–7]. Several of these guidelines [4, 5, 7] provide man-
agement guidance for PCLs with emphasis on high-risk 
features, including size greater than 3  cm, mural nod-
ules, and dilation of the main pancreatic duct. The 2017 
revised Fukuoka guidelines [5] propose using a cyst size 
greater than 3 cm as a worrisome feature to recommend 
EUS-FNA. The 2015 AGA guidelines [4] include cyst size 
greater than 3 cm as one of three high-risk features, along 
with dilation of the main pancreatic duct and presence 
of a mass or nodule, which should prompt an EUS-FNA, 
but only if two of these features are present simultane-
ously. Thus, in current clinical practice, for cysts greater 
than 3 cm, EUS-FNA is a reasonable next step.
Asymptomatic PCLs less than 3 cm without other wor-
risome features do not require EUS for evaluation. How-
ever, the described risk of malignancy in cysts smaller 
than 3  cm is about 6.5% and compares to 9% for cysts 
larger than 3 cm [8]. As such, the risk of missing malig-
nancy or high-grade dysplasia in small pancreatic cysts 
should be considered. The superior imaging quality of 
EUS and additional FNA for pancreatic cyst fluid (PCF) 
analysis, including carcinoembryonic antigen (CEA) and 
cytology, may allow definitive cyst classification [9]. CEA 
allows distinction of mucinous cysts [10] and cytology, 
despite scant cellularity [11] and interobserver agree-
ment limitations [12], may provide a definitive diagnosis 
of malignancy.
The aim of our study was to evaluate the diagnostic 
ability of EUS-FNA in pancreatic cysts smaller than 3 cm 
and assess its accuracy in small cysts referred for surgery.
Methods
Case selection
For this single-center retrospective study, we reviewed 
consecutive patients with PCLs submitted to EUS 
between 2007 and 2016, and selected all cysts smaller 
than 3  cm that were further evaluated with FNA, from 
our Endoscopic Ultrasound database and Pancreatic Cyst 
Registry, as approved by the Institutional Scientific Board 
and Ethics Committee (UIC/1143). For all patients, clini-
cal data, EUS morphology, PCF analysis (CEA, amyl-
ase and cytology), clinical decision, and follow-up were 
prospectively collected and registered. All patients gave 
informed consent for EUS-FNA, standard PCF analysis, 
and residual PCF storage.
The main criterion for patient selection was having 
been submitted to EUS-FNA for evaluation of a pancre-
atic cyst smaller than 3 cm. Cysts were separated in two 
groups, A and B, respectively, according to the presence 
or absence of a solid component. Patients were divided 
into a surgical cohort, with definitive surgical pathol-
ogy as reference standard for diagnosis, and a clinical 
cohort, with the diagnosis established by EUS-FNA with 
PCF analysis for CEA and/or cytology and morphologic 
stability after imaging surveillance for a minimum of six 
months.
EUS still-images were reviewed, with EUS findings, 
including cyst size, location, morphology (thick septa, 
wall thickening, or solid components, including mural 
nodule or mass that were defined as solid components 
inside or contiguous to the cyst, respectively), and main 
pancreatic duct features (dilation of 5–9  mm or cyst 
communication) retrieved from our database of prospec-
tively collected data.
We did not perform contrast harmonic EUS (CH-EUS) 
and EUS-FNA was performed with a 22 or 25-gauge nee-
dle, as per attending physician decision, according to cyst 
location and morphology, namely size, presence of solid 
component to sample, and pancreatic duct dilation. Cysts 
were fully aspirated when possible, with prophylactic 
intravenous administration of ciprofloxacin during the 
procedure, followed by five days of oral administration, 
as suggested by the 2013 ASGE guidelines [13] effec-
tive during the study period, with antibiotic prophylaxis 
recommended before and maintained during 3 to 5 days 
after the procedure.
The PCF obtained was immediately centrifuged for 
cytospin preparation for cytological analysis, and the 
supernatant was sent for CEA (Architect, Abbott; chemi-
luminescent immunoassay) and amylase (Architect, 
Abbott; kinetic colorimetric method).
Cysts were classified as mucinous, indeterminate, or 
non-mucinous according to a CEA level ≥ 192  ng/mL, 
between 192 ng/mL and 5 ng/mL, or < 5 ng/mL, respec-
tively. Cysts were further classified as benign serous 
cystadenomas (SCAs), in case of CEA level < 5  ng/mL 
with a matched or a non-diagnostic cytology. The cyto-
logical analysis of PCF, using the Papanicolaou Society 
of Cytopathology Guidelines [14], prompted cyst clas-
sification into three groups: (1) malignant cysts (MCs), 
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having atypical or malignant cells and other neoplastic 
cells (cystic adenocarcinomas—ADCs, neuroendocrine 
tumors—NETs or solid pseudopapillary neoplasms-
SPPNs); (2) pre-malignant cysts (PMCs) with mucinous 
benign epithelia without atypia or with low-grade atypia, 
including mucinous cystic neoplasms—MCNs and intra-
ductal papillary neoplasms—IPMNs; and (3) benign cysts 
(BCs) with inflammatory cells, neoplastic benign non-
mucinous cells, or other neoplastic cells, for example 
SCAs, pseudocysts, lymphangiomas.
After undergoing EUS-FNA, patients were referred 
for surgery (surgical cohort) or surveillance, palliation, 
or endoscopic treatment (clinical cohort), according to 
the consensus guidelines of Sendai 2006 [15] revised in 
Fukuoka in 2012 [16] and attending physician’s decision. 
Magnetic resonance imaging (MRI) or EUS were used in 
surveillance of the clinical cohort. The diagnostic accu-
racy of EUS-FNA was evaluated in the surgical cohort.
Statistical analysis
Descriptive data were expressed as mean ± SD or 
median, and range. Chi-square test or Fisher’s exact test 
were used to assess differences between cysts requiring 
surgery or surveillance, for dichotomous variables, and 
student t test or the Wilcoxon rank-sum test for continu-
ous variables. A statistical significance was defined as a p 
value < 0.05. The sensitivity, specificity, positive and nega-
tive predictive values, and diagnostic accuracy of EUS 
imaging, CEA level, and cytology in PCF were evaluated 
for the diagnosis of high-risk/malignant cysts in the sur-
gical cohort. Receiver operator curves were generated, 
and area under the curve (AUC) was calculated. Statisti-
cal analysis was performed using SPSS Statistics version 
23 (IBM Corp, Armonk, NY).
Results
Demographics and cyst characteristics
Of 167 patients referred to EUS for evaluation of PCLs 
smaller than 3 cm, FNA was not performed in 52 due to 
difficult location, small size, no worrisome features, or 
no visualization of the lesion. We present the features of 
FNA and non-FNA cohorts in Additional file 1: Table S1.
We further evaluated 115 patients with small cysts who 
underwent FNA for PCF analysis, including the surgical 
and clinical cohorts with 19 and 96 patients, respectively. 
Table 1 shows clinical, endosonographic, and PCF anal-
ysis features of all patients included. There were 49/115 
(42.6%) PCLs that were 2 cm or more in size and there 
were no patients with Wirsung dilation. Reasons for 
undergoing EUS-FNA included an initial diagnostic eval-
uation in 93 (80.8%), a change in cyst morphology dur-
ing surveillance in 11 (9.6%), and was not described in 11 
Table 1 Demographics, cyst morphological features, 
and PCF analysis
a Nodule/mass size available in 25 patients
b CEA available in 99 patients
c Amylase available in 96 patients
d Bad surgical candidates (2)/unresectable concomitant ADCs (3)
Patients, n 115
Females, n (%) 75 (65%)
Mean age, years
 Mean ± standard deviation (range) 63 ± 12 (33–86)
F-up time, months
 Mean ± standard deviation (range) 37 ± 30 (6–134)
Symptoms, n (%) 21 (18.3%)
Cysts, n 115
Location n, (%)
 Head 45 (39.1%)
 Body 42 (36.6%)
 Tail 23 (20%)
 Multiple 5 (4.3%)
Size, mm
 Mean ± standard deviation (range) 19 ± 6 (5–29)
Size, n (%)
 ≤ 10 mm 10 (8.7%)
 10–20 mm 56 (48.7%)
 ≥ 20 mm 49 (42.6%)
Mural nodule/mass, n (%) 31 (27%)
Mural nodule/mass, size (mm)
 Mean ± standard deviation (range) 16.2 ± 12.2 (2–49)
 Size > 10 mm, n (%)a 13 (52%)
Wirsung dilation, n (%) 0 (0%)
PCF analysis
CEA, n (%)b
 ≤ 5 ng/mL 18 (18.2%)
 5–192 ng/mL 42 (42.4%)
 ≥ 192 ng/mL 39 (39.4%)
Amylase, n (%)c
 < 250 UI/mL 38 (39.6%)
 ≥ 250 UI/mL 50 (60.4%)
Cytology
 Acellular 75 (65.2%)
 Benign or inflammatory 20 (17.4%)
 LGD 3 (2.6%)
 Malignant, atypical, NET 17 (14.8%)
Clinical decision after EUS-FNA, n (%)
 Surgery 19 (16.5%)
 Imaging surveillance 80 (69.6%)
 Palliationd 5 (4.3%)
 Lost to follow-up 11(9.6%)
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(9.6%) patients. No adverse events related to the proce-
dure were recorded in the present series.
By combining CEA level and cytology results in PCF, 
we found that in 18 PCLs with CEA level ≤ 5  ng/mL, 
cytology identified 1 malignant, 1 NET, and 3 benign 
lesions. For the 42 PCLs with a CEA level between 5 and 
192 ng/mL, cytology identified 2 atypical, 2 NETs, and 6 
benign lesions. For the 39 PCLs with a CEA ≥ 192 ng/mL, 
cytology identified 4 malignant, 7 mucinous (including 
3 samples with low-grade atypia), and 6 benign lesions. 
Considering cytology as the pre-surgical gold standard 
of malignancy, CEA values had considerable overlap in 
malignant and non-malignant cysts, without discrimina-
tive power (p = 0.053).
Surgical pathology diagnosis and EUS‑FNA diagnostic 
performance
Figure 1 shows the discriminative power of nodule/mass 
within the cyst in surgical patients. The overall rate of 
surgery in patients with cysts smaller than 3  cm evalu-
ated with FNA was 17% (19/115). In the subgroup of 31 
patients with a concomitant mass or nodule (Group A), 
the rate of surgery was 26% (8/31), while in the subgroup 
of 84 patients without mural nodule or mass (Group B), 
the surgery rate was 13% (11/84), p value of 0.092. High-
risk/malignant lesions were present in Group A (n = 3) 
and Group B (n = 4). Detailed data of lesions that under-
went surgery are shown in the Additional file 1: Table S2. 
Broadly, 7 malignant, 8 pre-malignant, and 4 benign 
PCLs were resected. The 7/19 (37%) malignant or high-
risk lesions resected included cystic ADCs (3), NETs (2), 
and IPMNs-ADC (2). As shown in Table 2, the accuracy 
of EUS imaging was improved by PCF analysis for cyto-
logical diagnosis of malignant cysts.
Table  3 compares demographic, clinical, and cystic 
features of patients harboring malignant/high risk and 
non-malignant lesions. Symptomatic lesions, mostly 
presenting with non-specific abdominal pain (Addi-
tional file 1: Table S2), with a larger size and presenting 
a nodule/mas or suspicious lymph nodes, with a conclu-
sive cytology, were more often malignant. Mural nod-
ules were relevant for diagnosis of mucinous malignant 
lesions, but not for other rare types of high-risk lesions 
(e.g. cystic NETs and ADCs), in which a thick wall 
Fig. 1 Flowchart with the pancreatic cysts studied by EUS-FNA and the diagnosis of 19 pancreatic cystic lesions that underwent surgery. ADCs 
adenocarcinomas, IPMNs intraductal papillary mucinous neoplasms, NETs neuroendocrine tumors, MCNs mucinous cystic neoplasms, SCAs serous 
cystadenomas
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justified FNA, with cytology rendering the final diagno-
sis. Although mural nodules correlate with malignancy, 
they are not pathognomonic, as they also occur in low-
risk lesions. Small cysts without worrisome features in 
patients with non-specific abdominal may correspond to 
malignant/high-risk lesions requiring surgery (Patients 3, 
8, and 9 in Additional file 1: Table S2).
Discussion
Our study endorses EUS-FNA with PCF analysis in cysts 
smaller than 3 cm, even if additional worrisome features 
(mural nodule/mass) are absent, due to its ability to diag-
nose malignant small PCLs pre-operatively. In our surgi-
cal series we found malignant and pre-malignant lesions 
in 15/115 patients (13%), which is similar to the rate of 
malignancy in lesions greater than 3 cm [17]. Combined 
EUS-FNA has better performance than isolated EUS 
imaging for malignant cyst diagnosis, with an area under 
the curve of 0.8 (95% CI 0.58–1).
In our series, we had 21/115 (18.3%) of symptomatic 
patients, with a striking difference in malignancy rates 
between symptomatic 12/17 (70.6%) and 9/98 (9.2%) 
asymptomatic patients, p < 0.0001. This finding high-
lights that EUS and FNA features should always be used 
in conjunction with clinical findings, as well as laboratory 
and other imaging techniques, in order to improve the 
differential of PCLs. In our cohort of 19 surgical resected 
cysts, we found 7/19 (37%) histologically high-risk/malig-
nant cysts, including NETs, IPMN-associated ADCs, 
and cystic ADCs. This rate of malignancy in small cysts 
is similar to 35.5% of histologically malignant cysts in 
lesions larger than 3 cm, as reported by Chebib et al. [17] 
and higher than other surgical series, with 16% of high-
risk malignant IPMNs, as reported by Ridtitid et al. [18], 
32% by Singhi et al. [19], and 29% by Lekkerkeker et al. 
[20]. Furthermore, 8/19 (42%) patients had pre-malignant 
cysts. Our results support the concept that size by itself 
should not be a decisive factor to perform or not FNA.
In order to select high-risk/malignant small cysts in 
this series, the presence of a nodule per se was not par-
ticularly helpful, with a 10% malignancy rate in resected 
cysts in Group A (with mural nodule/mass) versus 5% 
in Group B (without nodule/mass), p = NS. This would 
apparently support the recommendation of AGA guide-
lines requiring at least two worrisome features for fur-
ther evaluation of PCLs [4]. However, we had 5% of 
small cysts without worrisome features that were con-
firmed to be high-risk or malignant in surgical pathology 
Table 2 Performance characteristics of  EUS imaging, PCF fluid analysis (CEA and  cytology), and  EUS-FNA results 
(imaging, CEA and cytology) for malignant cysts identification
EUS endoscopic ultrasound, FNA fine-needle aspiration, PPV positive predictive value, NPV negative predictive value, CI confidence interval, ROC receiver-operating 
characteristics
Malignant cysts (7/19) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Accuracy (95% CI) Area under the ROC (CI)
EUS-imaging 38 (9–76) 55 (23–83) 33 (14–59) 60 (41–76) 48 (25–72) 0.60 (0.30–0.90)
EUS-FNA (CEA + cytol-
ogy)
86 (42–99) 50 (21–79) 50 (35–66) 86 (47–98) 63 (38–84) 0.80 (0.58–1.00)
Table 3 Demographics and cystic features in malignant versus non-malignant cysts in both cohorts
SD standard deviation
a Pain, weight loss, vomiting, jaundice, acute pancreatitis
Malignant (n = 17) Non‑malignant (n = 98) p value
Female n (%) 9 (52.6%) 65 (66.3%) 0.551
Mean age ± SD (range) 62.9 ± 12.3 (43–80) 63.1 ± 11.9 (33–86) 0.987
Symptomsa n (%) 12 (70.6%) 9 (9.2%) 0.000
Cyst location (head, body, tail, multiple) 10/5/2/0 35/37/21/5 0.059
Cyst size (mm) mean ± SD (range) 21.6 ± 6 (10–29) 18 ± 6.1 (5–29) 0.030
Cyst size > 20 mm 10 (58.8%) 33 (33.7%) 0.049
Septa n (%) 6 (35.3%) 56 (57.1%) 0.080
Nodule n (%) 10 (58.8%) 21 (21.4%) 0.001
Adenopathy n (%) 6 (35.3%) 1 (1%) 0.000
Amylase (U/L) ± SD (range) 3564 ± 10,644 (7–40,223) 41,437 ± 111,030 (3–786,486) 0.049
CEA (ng/mL) ± SD (range) 1522 ± 39,505 (5–150,490) 2725 ± 17,173 (1–155,012) 0.053
Conclusive cytology n (%) 14 (82.4%) 25 (25.8%) 0.001
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specimens, including two NETs and one cystic ADC, that 
presented with non-specific abdominal pain.
In a recent meta-analysis evaluating risk factors for 
malignancy and high-grade dysplasia exclusively in 
IPMNs, the presence of a nodule was considered rele-
vant, but not cyst size [21]. Our study includes relevant 
PCLs besides IPMNs, particularly two cystic NETs and 
a cystic ADC without associated nodules, that possibly 
explain the discrepancies in mural nodule significance 
with the previous study and current guidelines, that refer 
only to BD-IPMNs [5] and cannot be applied in other 
cyst types (e.g. cystic NET). Our study represents cur-
rent clinical practice, includes an heterogeneous group of 
cysts (NETs, IPMNs, SCAs, MCNs, etc.), in which cur-
rent guidelines can be misleading, as clinical decisions 
rely on a presumed diagnosis, that even with additional 
FNA for PCF analysis, seldom allows a definitive diag-
nosis. Our results are in line with previous publications 
[19, 22] and expert opinions [23], that AGA guidelines 
[4] may be imprecise in discriminating between neoplas-
tic and non-neoplastic cysts, and of limited value in early 
detection of pancreatic cancer. More recent guidelines, 
recommending EUS-FNA for PCF analysis in indetermi-
nate cysts, are probably more adequate for this purpose 
[6].
Additionally, in our series there were 18% (18/99) of 
patients with non-mucinous cysts after EUS-FNA (CEA 
level ≤ 5  ng/mL), supporting a strategy to stop surveil-
lance. However, in these 18 patients cytology identified 1 
malignant cyst and 1 NET, further reinforcing the value 
of cytology to definitely exclude malignancy. Similarly, 
there were 42% (42/99) of PCLs with a CEA level between 
5 and 192  ng/mL, considered indeterminate for muci-
nous cyst diagnosis, with cytology diagnosing 4 high risk/
malignant lesions—2 atypical and 2 NETs. Using CEA 
level ≥ 192 ng/mL as cut-off for mucinous cysts diagnosis 
would reduce sensitivity and exclude several mucinous 
lesions from surveillance. This imperfect performance of 
CEA highlights the need of better biomarkers in PCLs. 
PCF glucose may be more advantageous than CEA in 
routine diagnosis of small pancreatic mucinous cysts, 
reducing “indeterminate” diagnosis and requiring mini-
mal amount of PCF as shown by others and ourselves in a 
recently published study [24–26].
The value of EUS in diagnosis and staging of malig-
nancy and its clinical impact on patient management 
has been previously established [27]. Moreover, CH-EUS 
is a useful adjunct in the differential of pancreatic cysts 
[28] that shows malignant vegetations as solid compo-
nents with hyperenhancement, thus allowing to direct 
EUS-FNA to potential neoplastic areas while avoiding 
puncture of debris and mucus plugs. CH-EUS allows the 
differentiation between pseudocysts and other PCLs, but 
not between MCNs and SCAs. Therefore CH-EUS does 
not replace FNA and should be used in conjunction with 
clinical, laboratory, and other imaging techniques in the 
differential diagnosis of PCLs.
No adverse events occurred in our study. We did not 
transverse more that 10 mm of pancreatic parenchyma or 
crossed the wirsung duct to avoid pancreatitis. Besides, 
cysts were fully aspirated when possible and prophylac-
tic intravenous administration of ciprofloxacin during the 
procedure, was followed by 5 days of oral administration 
in all cases, as per 2013 ASGE guidelines [13]. These were 
effective during the study period, and recommended 
antibiotic prophylaxis before and 3 to 5 days after EUS-
FNA, although the conflicting evidence. Recent evidence 
from a randomized trial published in 2020, showed that 
antibiotic prophylaxis might not be needed at all before 
EUS-FNA of pancreatic cysts [29].
Our study has several strengths. The main is to evaluate 
PCLs assessed by EUS-FNA as standard of care includ-
ing predominantly low-risk PCLs, better representing 
daily practice. Moreover, the patient and cyst data were 
prospectively collected and registered with most PCLs 
with CEA and cytology evaluation. We had CEA level for 
most PCLs, but cytology was informative in only 33% of 
patients, which compares to 76% in lesions larger than 
3 cm [17].
The limitations of our study include its retrospective 
design, which may have introduced unintended biases, 
the modest sample size, and the low number of surgi-
cal pathology diagnoses. Also, we evaluated cyst mor-
phology by EUS, not by other imaging methods because 
several patients were outside referrals without images 
available for review. Finally, we studied diagnostic accu-
racy of EUS-FNA exclusively in resected cysts due to 
possible diagnostic uncertainty of the clinical cohort, in 
which diagnosis relied on clinico-cytological features.
In summary, when debating the role of EUS-FNA 
in pancreatic cysts smaller than 3  cm, one can support 
either side of the coin. On the one hand, we found most 
PCF analysis inconclusive (more than 40% of CEA levels 
between 5 and 192 ng/mL, and overall two thirds of acel-
lular samples) making EUS-FNA an invasive and often 
unhelpful technique. On the other, EUS-FNA allowed to 
diagnose malignancy in some patients who would oth-
erwise be surveilled, potentially improving outcome and 
cost-effectiveness of the program. Mass/nodules were 
helpful for malignant cyst diagnosis, although absent 
in cystic NETs and cystic PDACs with central necrosis, 
while often occurring in non-high-risk IPMNs. As the 
performance of any isolated marker is imperfect, accord-
ing to our results, combining clinical, morphologic, bio-
chemical, and cytological data significantly improves 
the diagnosis of malignancy. Furthermore, EUS-FNA 
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diagnosed benign cysts in almost 1 in every 5 patients, 
allowing their release from invasive and costly surveil-
lance programs. Surveillance is especially important 
in young and healthy patients, while discontinuation 
is advisable in elderly individuals with increased risk of 
death from other causes than pancreatic cancer.
Conclusion
EUS-FNA allows pre-operative diagnosis of small PCLs 
harboring malignancy. Finding new and more specific 
biomarkers may also enhance this strategy.
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